Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of Relacorilant in Healthy Subjects
NCT03508635Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2014
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of relacorilant in Cushing's syndrome (9 arms), sponsored by Corcept Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Sep 2014; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT03508635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508635.